Browse through our press and news section by category:

26.07.2017, St Gallen, Switzerland

In light of growing demand, SCHOTT again increases its polymer syringe production

Double-digit million-euro amount invested in Swiss competence center
Global pharma packaging specialist SCHOTT will double the capacity at its syringe competence center in Switzerland following significant facility investments. At the St. Gallen site, which has already seen a capacity increase in recent years, additional production began in June. Further capacity is being installed and will be in operation next year. The development meets the growing demand for applications that drive the market for pre-filled polymer syringes.

“Polymer syringes have a number of advantages for certain applications,” said Product Manager Tom Van Ginneken. “The material maintains glass-like transparency and is resistant to breakage. The excellent barrier properties of the SCHOTT TopPac® syringe system in particular keep the medication stable throughout its shelf life. In addition, injection molding allows for higher customization options and tighter product tolerances. These advantages support the market growth in applications such as highly viscous drugs, emergency drugs and intensive care.”

The new production capacity will integrate seamlessly into SCHOTT’s existing setup and advanced technologies. In this unique facility design, SCHOTT TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection molding to the final packaging in nest and tub. Afterwards, the syringes are sterilized and ready for aseptic filling operations.

Enhanced knowledge
Since 1996, SCHOTT gained profound experience and knowledge in manufacturing glass and polymer syringes, which paved the way for developing a complete portfolio with both materials used in a variety of applications. These include heparin, vaccines, biotech, and special applications such as intensive care. 

SCHOTT polymer syringes are available in 1 ml to 50 ml sizes, and are delivered in a nest-and-tub configuration, ready for the filling process. For more sensitive applications, SCHOTT TopPac® SD features for a reduced extractable and leachable profile and ensures high drug stability. In addition, an R&D team constantly works on new solutions and applications for new industry demands. The result are unique features such as improved production design or an enhanced siliconization process, contributing to the company’s strong worldwide market position with regard to polymer syringes.

SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 34 countries. With its workforce of approximately 15,000 employees, sales of 1.99 billion euros were generated in fiscal year 2015/2016. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.
Press contact
Christina Rettig
Public Relations Manager
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4094
Further information
Salvatore Ruggiero
Vice President Marketing and Communication
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4140